Published in Clin Exp Immunol on July 01, 2006
The Nrf2-antioxidant response element signaling pathway and its activation by oxidative stress. J Biol Chem (2009) 5.80
Fumarates improve psoriasis and multiple sclerosis by inducing type II dendritic cells. J Exp Med (2011) 1.81
Cellular stress responses, the hormesis paradigm, and vitagenes: novel targets for therapeutic intervention in neurodegenerative disorders. Antioxid Redox Signal (2010) 1.77
Mechanisms of neurodegeneration and axonal dysfunction in multiple sclerosis. Nat Rev Neurol (2014) 1.46
Dimethyl Fumarate Ameliorates Lewis Rat Experimental Autoimmune Neuritis and Mediates Axonal Protection. PLoS One (2015) 1.46
Dimethylfumarate inhibits microglial and astrocytic inflammation by suppressing the synthesis of nitric oxide, IL-1beta, TNF-alpha and IL-6 in an in-vitro model of brain inflammation. J Neuroinflammation (2010) 1.41
G protein-coupled receptors for energy metabolites as new therapeutic targets. Nat Rev Drug Discov (2012) 1.35
Fumarates modulate microglia activation through a novel HCAR2 signaling pathway and rescue synaptic dysregulation in inflamed CNS. Acta Neuropathol (2015) 1.28
Hydroxycarboxylic acid receptor 2 mediates dimethyl fumarate's protective effect in EAE. J Clin Invest (2014) 1.24
The anti-inflammatory effects of dimethyl fumarate in astrocytes involve glutathione and haem oxygenase-1. ASN Neuro (2011) 1.19
Fumaric Acid and its esters: an emerging treatment for multiple sclerosis. Curr Neuropharmacol (2009) 1.15
Cell type-specific Nrf2 expression in multiple sclerosis lesions. Acta Neuropathol (2015) 1.15
The benefits and detriments of macrophages/microglia in models of multiple sclerosis. Clin Dev Immunol (2013) 1.14
The Nrf2-ARE pathway: a valuable therapeutic target for the treatment of neurodegenerative diseases. Recent Pat CNS Drug Discov (2012) 1.13
The experimental autoimmune encephalomyelitis (EAE) model of MS: utility for understanding disease pathophysiology and treatment. Handb Clin Neurol (2014) 1.11
Teriflunomide and its mechanism of action in multiple sclerosis. Drugs (2014) 1.08
Animal models of multiple sclerosis for the development and validation of novel therapies - potential and limitations. J Neurol (2008) 1.08
The role of the immune system in Huntington's disease. Clin Dev Immunol (2013) 1.03
Models of autoimmune demyelination in the central nervous system: on the way to translational medicine. Exp Transl Stroke Med (2009) 1.03
Mechanisms of oxidative damage in multiple sclerosis and neurodegenerative diseases: therapeutic modulation via fumaric acid esters. Int J Mol Sci (2012) 1.02
Dimethyl fumarate, an immune modulator and inducer of the antioxidant response, suppresses HIV replication and macrophage-mediated neurotoxicity: a novel candidate for HIV neuroprotection. J Immunol (2011) 0.99
Dimethyl fumarate in the treatment of relapsing-remitting multiple sclerosis: an overview. Ther Adv Neurol Disord (2015) 0.95
Nrf2-a therapeutic target for the treatment of neurodegenerative diseases. Free Radic Biol Med (2015) 0.95
Effects of fumaric acids on cuprizone induced central nervous system de- and remyelination in the mouse. PLoS One (2010) 0.94
Can we switch microglia's phenotype to foster neuroprotection? Focus on multiple sclerosis. Immunology (2014) 0.93
BG-12 reduces evolution of new enhancing lesions to T1-hypointense lesions in patients with multiple sclerosis. J Neurol (2010) 0.92
Optimizing therapeutics in the management of patients with multiple sclerosis: a review of drug efficacy, dosing, and mechanisms of action. Biologics (2013) 0.92
Dimethyl fumarate treatment alters circulating T helper cell subsets in multiple sclerosis. Neurol Neuroimmunol Neuroinflamm (2015) 0.91
Design of oral agents for the management of multiple sclerosis: benefit and risk assessment for dimethyl fumarate. Drug Des Devel Ther (2014) 0.90
Targeting heme oxygenase-1 and carbon monoxide for therapeutic modulation of inflammation. Transl Res (2015) 0.90
Recent advances in treating multiple sclerosis: efficacy, risks and place in therapy. Ther Adv Chronic Dis (2013) 0.90
Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study. Neurology (2015) 0.88
Metabolic reprograming of mononuclear phagocytes in progressive multiple sclerosis. Front Immunol (2015) 0.87
Dimethyl Fumarate Protects Neural Stem/Progenitor Cells and Neurons from Oxidative Damage through Nrf2-ERK1/2 MAPK Pathway. Int J Mol Sci (2015) 0.86
Dimethyl fumarate in multiple sclerosis: latest developments, evidence and place in therapy. Ther Adv Chronic Dis (2016) 0.85
Pharmacology and clinical efficacy of dimethyl fumarate (BG-12) for treatment of relapsing-remitting multiple sclerosis. Ther Clin Risk Manag (2014) 0.85
Myeloid cells - targets of medication in multiple sclerosis. Nat Rev Neurol (2016) 0.83
Dimethyl fumarate modulation of immune and antioxidant responses: application to HIV therapy. Crit Rev Immunol (2013) 0.83
Monomethylfumarate reduces in vitro migration of mononuclear cells. Neurol Sci (2014) 0.82
Development of oral immunomodulatory agents in the management of multiple sclerosis. Drug Des Devel Ther (2011) 0.81
Fumaric Acid Esters Do Not Reduce Inflammatory NF-κB/p65 Nuclear Translocation, ICAM-1 Expression and T-Cell Adhesiveness of Human Brain Microvascular Endothelial Cells. Int J Mol Sci (2015) 0.81
What do effective treatments for multiple sclerosis tell us about the molecular mechanisms involved in pathogenesis? Int J Mol Sci (2012) 0.81
Inflammatory targets of therapy in sickle cell disease. Transl Res (2015) 0.80
New approaches to treating Alzheimer's disease. Perspect Medicin Chem (2015) 0.79
A novel CMKLR1 small molecule antagonist suppresses CNS autoimmune inflammatory disease. PLoS One (2014) 0.79
Monomethyl fumarate augments NK cell lysis of tumor cells through degranulation and the upregulation of NKp46 and CD107a. Cell Mol Immunol (2014) 0.79
Dimethyl fumarate attenuates experimental autoimmune neuritis through the nuclear factor erythroid-derived 2-related factor 2/hemoxygenase-1 pathway by altering the balance of M1/M2 macrophages. J Neuroinflammation (2016) 0.78
Oral disease-modifying therapies for multiple sclerosis. J Clin Neurol (2015) 0.78
Untargeted Plasma Metabolomics Identifies Endogenous Metabolite with Drug-like Properties in Chronic Animal Model of Multiple Sclerosis. J Biol Chem (2015) 0.77
Utilization of Dimethyl Fumarate and Related Molecules for Treatment of Multiple Sclerosis, Cancer, and Other Diseases. Front Immunol (2016) 0.77
New and Emerging Disease-Modifying Therapies for Relapsing-Remitting Multiple Sclerosis: What is New and What is to Come. J Cent Nerv Syst Dis (2012) 0.77
Treatment With Dimethyl Fumarate Attenuates Calcineurin Inhibitor-induced Nephrotoxicity. Transplantation (2015) 0.76
The multicomponent medication lymphomyosot improves the outcome of experimental lymphedema. Lymphat Res Biol (2013) 0.76
Sex hormonal regulation and hormesis in aging and longevity: role of vitagenes. J Cell Commun Signal (2014) 0.76
Dimethyl fumarate. Hosp Pharm (2013) 0.76
Dimethyl fumarate treatment of relapsing-remitting multiple sclerosis influences B-cell subsets. Neurol Neuroimmunol Neuroinflamm (2016) 0.76
Dimethyl fumarate in the management of multiple sclerosis: appropriate patient selection and special considerations. Ther Clin Risk Manag (2016) 0.75
Fumarate modulates the immune/inflammatory response and rescues nerve cells and neurological function after stroke in rats. J Neuroinflammation (2016) 0.75
Protandim Protects Oligodendrocytes against an Oxidative Insult. Antioxidants (Basel) (2016) 0.75
The Effect of Dimethyl Fumarate on Cerebral Gray Matter Atrophy in Multiple Sclerosis. Neurol Ther (2016) 0.75
Monomethyl fumarate (MMF) inhibits pain behaviors and amygdala activity in a rat arthritis model. Pain (2017) 0.75
Regulation of human glia by multiple sclerosis disease modifying therapies. Semin Immunopathol (2015) 0.75
Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol (2001) 25.63
Psoriasis. N Engl J Med (2005) 8.56
Th1 and Th2 CD4+ T cells in the pathogenesis of organ-specific autoimmune diseases. Immunol Today (1995) 5.32
Experimental autoimmune encephalomyelitis repressed by microglial paralysis. Nat Med (2005) 4.42
T-lymphocyte entry into the central nervous system. J Neurosci Res (1991) 4.28
Granulocyte macrophage colony-stimulating factor: a new putative therapeutic target in multiple sclerosis. J Exp Med (2001) 2.60
Role of macrophages/microglia in multiple sclerosis and experimental allergic encephalomyelitis. J Mol Med (Berl) (1997) 2.55
IL-10 is involved in the suppression of experimental autoimmune encephalomyelitis by CD25+CD4+ regulatory T cells. Int Immunol (2004) 2.11
CNTF is a major protective factor in demyelinating CNS disease: a neurotrophic cytokine as modulator in neuroinflammation. Nat Med (2002) 1.91
Inflammatory central nervous system demyelination: correlation of magnetic resonance imaging findings with lesion pathology. Ann Neurol (1997) 1.90
Phagocytic activity of macrophages and microglial cells during the course of acute and chronic relapsing experimental autoimmune encephalomyelitis. J Neurosci Res (1994) 1.70
Treatment of psoriasis with fumaric acid esters: results of a prospective multicentre study. German Multicentre Study. Br J Dermatol (1998) 1.67
Selective stimulation of T helper 2 cytokine responses by the anti-psoriasis agent monomethylfumarate. Eur J Immunol (1996) 1.52
Animal models for autoimmune demyelinating disorders of the nervous system. Mol Med Today (2000) 1.49
Dimethylfumarate is a potent inducer of apoptosis in human T cells. J Invest Dermatol (2003) 1.49
Oral fumaric acid esters for the treatment of active multiple sclerosis: an open-label, baseline-controlled pilot study. Eur J Neurol (2006) 1.44
Dimethylfumarate inhibits TNF-induced nuclear entry of NF-kappa B/p65 in human endothelial cells. J Immunol (2002) 1.39
Treatment of severe psoriasis with fumaric acid esters: scientific background and guidelines for therapeutic use. The German Fumaric Acid Ester Consensus Conference. Br J Dermatol (1999) 1.34
Inhibition of dendritic cell differentiation by fumaric acid esters. J Invest Dermatol (2001) 1.16
Monomethylfumarate affects polarization of monocyte-derived dendritic cells resulting in down-regulated Th1 lymphocyte responses. Eur J Immunol (2004) 1.14
Influence of monomethylfumarate on monocytic cytokine formation--explanation for adverse and therapeutic effects in psoriasis? Arch Dermatol Res (1997) 1.09
Presystemic metabolism and intestinal absorption of antipsoriatic fumaric acid esters. Biopharm Drug Dispos (2003) 1.03
The immunology of multiple sclerosis and its animal model, experimental allergic encephalomyelitis. Neurol Clin (1995) 1.02
Protease production by cultured microglia: substrate gel analysis and immobilized matrix degradation. J Neurosci Res (1993) 0.92
Improvement of herpetic stromal keratitis with fumaric acid derivate is associated with systemic induction of T helper 2 cytokines. Clin Exp Immunol (2005) 0.83
Pseudomonas cepacia infection in cystic fibrosis: an emerging problem. J Pediatr (1984) 9.61
Development of a short 'readiness to change' questionnaire for use in brief, opportunistic interventions among excessive drinkers. Br J Addict (1992) 5.02
Prevention of meningococcal disease by group C polysaccharide vaccine. N Engl J Med (1970) 4.90
Carriage of Neisseria meningitidis and Neisseria lactamica in infants and children. J Infect Dis (1978) 4.00
Cutaneous reactions and antibody response to meningococcal group C polysaccharide vaccines in man. J Infect Dis (1970) 2.71
Objective measurement of wave aberrations of the human eye with the use of a Hartmann-Shack wave-front sensor. J Opt Soc Am A Opt Image Sci Vis (1994) 2.67
Meningococcal infections. 2. Field trial of group C meningococcal polysaccharide vaccine in 1969-70. Bull World Health Organ (1971) 2.64
Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort. Neurology (2012) 2.60
The pathology of the joint tissues and its clinical relevance in prosthesis failure. Clin Orthop Relat Res (1976) 2.46
Disseminated fusarial infection in the immunocompromised host. Rev Infect Dis (1989) 2.46
Pulmonary function and clinical course in patients with cystic fibrosis after pulmonary colonization with Pseudomonas aeruginosa. J Pediatr (1990) 2.28
2.5 year remission of AIDS-associated progressive multifocal leukoencephalopathy with combined antiretroviral therapy. Lancet (1997) 2.28
Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy. Neurology (2011) 2.26
Adverse reactions to diphtheria, tetanus, pertussis-polio vaccination at 18 months of age: effect of injection site and needle length. Pediatrics (1989) 2.21
Acetaminophen prophylaxis of adverse reactions following vaccination of infants with diphtheria-pertussis-tetanus toxoids-polio vaccine. Pediatr Infect Dis J (1987) 2.20
Identification of an epidemic strain of group C Neisseria meningitidis by bactericidal serotyping. J Infect Dis (1971) 2.17
Clinical evaluation of group A and group C meningococcal polysaccharide vaccines in infants. J Clin Invest (1975) 2.16
Results from the 1995 National College Health Risk Behavior Survey. J Am Coll Health (1997) 2.13
Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function. Neurology (2009) 2.10
[Fumaric acid as therapeutic agent for multiple sclerosis]. Nervenarzt (2014) 1.97
Gene expression profiling of the nervous system in murine experimental autoimmune encephalomyelitis. Brain (2001) 1.91
Etiology of acute childhood encephalitis at The Hospital for Sick Children, Toronto, 1994-1995. Clin Infect Dis (1998) 1.85
Differential regulation of the alpha/beta interferon-stimulated Jak/Stat pathway by the SH2 domain-containing tyrosine phosphatase SHPTP1. Mol Cell Biol (1995) 1.83
Survey of parents' attitudes to the recommended Haemophilus influenzae type b vaccine program. CMAJ (1987) 1.72
Kinetics of antibody production to group A and group C meningococcal polysaccharide vaccines administered during the first six years of life: prospects for routine immunization of infants and children. J Infect Dis (1979) 1.67
Ceftazidime alone and in combination in patients with cystic fibrosis: lack of efficacy in treatment of severe respiratory infections caused by Pseudomonas cepacia. J Antimicrob Chemother (1983) 1.60
Endothelial leukocyte adhesion molecule 1: direct expression cloning and functional interactions. Proc Natl Acad Sci U S A (1990) 1.59
Persistence of antibody following immunization of children with groups A and C meningococcal polysaccharide vaccines. Pediatrics (1977) 1.50
A blocking monoclonal antibody to endothelial-leukocyte adhesion molecule-1 (ELAM1). Biochem Biophys Res Commun (1990) 1.50
Apoptosis of T lymphocytes in experimental autoimmune encephalomyelitis. Evidence for programmed cell death as a mechanism to control inflammation in the brain. Am J Pathol (1993) 1.50
Superficial siderosis of the central nervous system: pathogenetic heterogeneity and therapeutic approaches. Acta Neurol Scand (2003) 1.49
Basic and escalating immunomodulatory treatments in multiple sclerosis: current therapeutic recommendations. J Neurol (2008) 1.46
["Chronic cerebrospinal venous insufficiency" and multiple sclerosis: critical analysis and first observation in an unselected cohort of MS patients]. Nervenarzt (2010) 1.45
A new histologic approach to the differentiation of enchondroma and chondrosarcoma of the bones. A clinicopathologic analysis of 51 cases. Clin Orthop Relat Res (1985) 1.42
Intravenous Immunoglobulins in MS. Int MS J (2005) 1.41
Treating HIV encephalopathy with antiretroviral therapy: a clinical case demonstrating the success of HAART. Clin Infect Dis (2004) 1.41
Chronic recurrent multifocal osteomyelitis: a noninfectious inflammatory process. Pediatr Infect Dis J (1987) 1.37
Thymomas alter the T-cell subset composition in the blood: a potential mechanism for thymoma-associated autoimmune disease. Blood (2000) 1.35
Giant axonal neuropathy. A clinically and morphologically distinct neurological disease. Arch Neurol (1974) 1.34
Long-term effects of inhaled tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa. Pediatr Pulmonol (1989) 1.31
A specific circulating antigen in hamsters infected with Schistosoma mansoni. Detection of antigen in serum and urine, and correlation between antigenic concentration and worm burden. Am J Trop Med Hyg (1969) 1.30
The crystal structure of human interferon beta at 2.2-A resolution. Proc Natl Acad Sci U S A (1997) 1.29
The sequelae of Haemophilus influenzae meningitis in school-age children. N Engl J Med (1990) 1.27
The Immunization Monitoring Program Active (IMPACT) prospective five year study of Canadian children hospitalized for chickenpox or an associated complication. Pediatr Infect Dis J (2000) 1.27
Adenoviral pneumonia and its complications in infancy and childhood. J Can Assoc Radiol (1969) 1.20
Controlled trial of ceftazidime vs. ticarcillin and tobramycin in the treatment of acute respiratory exacerbations in patients with cystic fibrosis. Pediatr Infect Dis (1985) 1.19
Plasma exchange for severe optic neuritis: treatment of 10 patients. Neurology (2004) 1.19
Microglial phagocytosis of apoptotic inflammatory T cells leads to down-regulation of microglial immune activation. J Immunol (2001) 1.18
Sequelae of acute bacterial meningitis in children treated for seven days. Pediatrics (1986) 1.17
Fumaric Acid and its esters: an emerging treatment for multiple sclerosis. Curr Neuropharmacol (2009) 1.15
Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study. Neurology (2005) 1.14
Diffusion of ions in myelinated nerve fibers. Biophys J (1979) 1.14
Immune Response of human infants of polysaccharide vaccines of group A and C Neisseria meningitidis. J Infect Dis (1977) 1.13
Administration of measles, mumps, and rubella virus vaccine (live) to egg-allergic children. JAMA (1990) 1.12
Epidemiologic study of 4684 hospital-acquired infections in pediatric patients. Pediatr Infect Dis J (1989) 1.12
Analysis of the performance of the Hartmann-Shack sensor in the human eye. J Opt Soc Am A Opt Image Sci Vis (2000) 1.12
High-dose methylprednisolone therapy in multiple sclerosis induces apoptosis in peripheral blood leukocytes. Arch Neurol (2001) 1.10
Antibiotic prophylaxis in cystic fibrosis: inhaled cephaloridine as an adjunct to oral cloxacillin. J Pediatr (1982) 1.09
Gene transfer through the blood-nerve barrier: NGF-engineered neuritogenic T lymphocytes attenuate experimental autoimmune neuritis. Nat Med (1995) 1.08
Analysis of the mouse gamma-crystallin gene family: assignment of multiple cDNAs to discrete genomic sequences and characterization of a representative gene. Nucleic Acids Res (1984) 1.08
[Treatment of relapsing-remitting multiple sclerosis with recombinant interferon-beta preparations]. Nervenarzt (2001) 1.08
Diagnostic accuracy of CT angiography and CT perfusion for cerebral vasospasm: a meta-analysis. AJNR Am J Neuroradiol (2010) 1.08
Oral laquinimod in patients with relapsing-remitting multiple sclerosis: 36-week double-blind active extension of the multi-centre, randomized, double-blind, parallel-group placebo-controlled study. Mult Scler (2010) 1.07
A practical guide for the diagnosis and treatment of pediatric pneumonia. CMAJ (1997) 1.06
Th17 Cells in MS and Experimental Autoimmune Encephalomyelitis. Int MS J (2009) 1.06
A symposium: Should homosexuality be in the APA nomenclature? Am J Psychiatry (1973) 1.06
Apoptosis of myelin-reactive T cells induced by reactive oxygen and nitrogen intermediates in vitro. Cell Immunol (1997) 1.06
Influenza vaccination of high-risk children: a survey of three physician groups. Can J Public Health (1999) 1.06
Reproductive counselling, treatment and course of pregnancy in 73 German MS patients. Acta Neurol Scand (2008) 1.04
Arthritis associated with Haemophilus influenzae meningitis: septic or reactive? J Pediatr (1986) 1.04
Deficiency of the autoimmune regulator AIRE in thymomas is insufficient to elicit autoimmune polyendocrinopathy syndrome type 1 (APS-1). J Pathol (2007) 1.04
Meningococcal meningitis in familial deficiency of the fifth component of complement. Pediatrics (1981) 1.03
Immune deficiency in mouse models for inherited peripheral neuropathies leads to improved myelin maintenance. J Neurosci (2000) 1.03
Pseudomonas species contamination of cystic fibrosis patients' home inhalation equipment. J Pediatr (1987) 1.03
Ceftazidime disposition in acute and stable cystic fibrosis. Clin Pharmacol Ther (1984) 1.03
Expression of specific matrix metalloproteinases in inflammatory myopathies. Brain (2001) 1.02
The role of the cytoskeleton in eukaryotic protein synthesis. (A minireview). Cell Biol Int Rep (1983) 1.01
ABC-transporter gene-polymorphisms are potential pharmacogenetic markers for mitoxantrone response in multiple sclerosis. Brain (2009) 0.99
The incidence of viral-associated diarrhea after admission to a pediatric hospital. Am J Epidemiol (1990) 0.99
MHC class I-mediated cytotoxicity does not induce apoptosis in muscle fibers nor in inflammatory T cells: studies in patients with polymyositis, dermatomyositis, and inclusion body myositis. J Neuropathol Exp Neurol (1996) 0.99
Bacterial meningitis--1982. Am J Med (1983) 0.99
Efficacy of inhaled tobramycin in the treatment of pulmonary exacerbations in children with cystic fibrosis. Pediatr Infect Dis (1983) 0.97
Cloxacillin absorption and disposition in cystic fibrosis. J Pediatr (1984) 0.96
Mycophenolate mofetil in the therapy of severe myasthenia gravis. Eur Neurol (2001) 0.96
Role of urethrocystoscopy in the evaluation of refractory idiopathic detrusor instability. Urology (2001) 0.96
Pertussis vaccine: myths and realities. Can Fam Physician (1988) 0.95
Conformational relevance of the beta6Glu replaced by Val mutation in the beta subunits and in the beta(1-55) and beta(1-30) peptides of hemoglobin S. J Biol Chem (1976) 0.95
Risk factors for severe perineal injury during childbirth: a case-control study of 60 consecutive cases. Colorectal Dis (2011) 0.94
Leptin attenuates follicular apoptosis and accelerates the onset of puberty in immature rats. Mol Cell Endocrinol (2001) 0.94
Escherichia coli ribosomal protein S1 recognizes two sites in bacteriophage Qbeta RNA. J Biol Chem (1977) 0.94
[Plasma exchange therapy for steroid-unresponsive multiple sclerosis relapses: clinical experience with 16 patients]. Nervenarzt (2006) 0.94
Mitoxantrone induces cell death in peripheral blood leucocytes of multiple sclerosis patients. Clin Exp Immunol (2005) 0.93
Clinical and microbiologic features of children presenting with pertussis to a Canadian pediatric hospital during an eleven-year period. Pediatr Infect Dis J (1994) 0.93
Altered innate immune response of plasmacytoid dendritic cells in multiple sclerosis. Clin Exp Immunol (2009) 0.93
Molecular mechanisms of high-dose antigen therapy in experimental autoimmune encephalomyelitis: rapid induction of Th1-type cytokines and inducible nitric oxide synthase. J Immunol (2000) 0.93